title: Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
abstract: Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes. Antiviral activity of elbasvir was measured in replicons derived from wild-type or resistant variants of genotypes 1a, 1b, and 3. The barrier to resistance was assessed by the number of resistant colonies selected by exposure to various elbasvir concentrations. In a phase 1b dose-escalating study, virologic responses were determined in 48 noncirrhotic adult men with chronic genotype 1 or 3 infections randomized to placebo or elbasvir from 5 to 50 mg (genotype 1) or 10 to 100 mg (genotype 3) once daily for 5 days. The NS5A gene was sequenced from plasma specimens obtained before, during, and after treatment. Elbasvir suppressed the emergence of resistance-associated variants (RAVs) in vitro in a dose-dependent manner. Variants selected by exposure to high elbasvir concentrations typically encoded multiple amino acid substitutions (most commonly involving loci 30, 31, and 93), conferring high-level elbasvir resistance. In the monotherapy study, patients with genotype 1b had greater reductions in HCV RNA levels than patients with genotype 1a at all elbasvir doses; responses in patients with genotype 3 were generally less pronounced than for genotype 1, particularly at lower elbasvir doses. M28T, Q30R, L31V, and Y93H in genotype 1a, L31V and Y93H in genotype 1b, and A30K, L31F, and Y93H in genotype 3 were the predominant RAVs selected by elbasvir monotherapy. Virologic findings in patients were consistent with the preclinical observations. NS5A-RAVs emerged most often at amino acid positions 28, 30, 31, and 93 in both the laboratory and clinical trial. (The MK-8742 P002 trial has been registered at ClinicalTrials.gov under identifier NCT01532973.).
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA Rongl876@gmail.com ahowe@cfenet.ubc.ca.
authors: Rong
authors: R
authors: Liu
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Stephanie
authors: S
authors: Curry
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Patricia
authors: P
authors: McMonagle
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Wendy W
authors: WW
authors: Yeh
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Steven W
authors: SW
authors: Ludmerer
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Patricia A
authors: PA
authors: Jumes
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: William L
authors: WL
authors: Marshall
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Stephanie
authors: S
authors: Kong
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Paul
authors: P
authors: Ingravallo
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Stuart
authors: S
authors: Black
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Irene
authors: I
authors: Pak
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.
authors: Mark J
authors: MJ
authors: DiNubile
authors: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA Rongl876@gmail.com ahowe@cfenet.ubc.ca.
authors: Anita Y M
authors: AY
authors: Howe
mesh_terms: D000293:Adolescent; D000328:Adult; D001572:Benzofurans / Q000494:pharmacology*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D012093:Replicon / Q000235:genetics; D055815:Young Adult
chemical_list: D001572:Benzofurans; D007093:Imidazoles; C000589335:elbasvir